AUTHORS
Wen-Juan Yu, MD, Lingyan Ping, MD2, Yongjing Tang3, Jing Li4, Lin Zhu5, Jie Jin, MD6, Yuqin Song, MD7
AFFILIATIONS
1 The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, China
2 Peking University Cancer Hospital, Beijing, China
3 Peking University Cancer Hospital, Beijing, China
4 Shanghai AbelZeta Ltd., Shanghai, China
5 Shanghai AbelZeta Ltd., Shanghai, China
6 The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, China
7 Peking University Cancer Hospital, Beijing, China
ABSTRACT
Background:
Prizloncabtagene autoleucel (prizlon-cel), formerly known as C-CAR039 or JNJ-90014496, is an autologous anti-CD20/CD19 bispecific CAR-T. We previously reported outcomes from an investigator-initiated trial (IIT) of prizlon-cel at 2026 EBMT conference (abstract A048), which demonstrated encouraging efficacy and a favorable safety profile in patients with r/r B-NHL. The best overall response rate (ORR) was 91.5%, with a complete response (CR) rate of 85.1%. At a median follow-up of 53.9 months, median progression-free survival (PFS) was 60.1 months, and median overall survival (OS) was not reached. A registrational Phase 1b/2 ELEVATION study (NCT05800977) is currently underway in China to further evaluate prizlon-cel in patients with large B-cell lymphoma (LBCL). Here, we present the results from phase 1b of the ELEVATION study.
Methods:
Patients with r/r diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), primary mediastinal large B-cell lymphoma (PMBCL), transformed follicular lymphoma (tFL), high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBL-DH/TH), high-grade B-cell lymphoma, NOS (HGBL, NOS), and follicular lymphoma grade 3B (FL3B) were enrolled and received a single prizlon-cel infusion at 2.5×106 CAR-T cells/kg. Primary endpoints of phase 1b study included incidence and severity of dose limiting toxicities (DLTs), incidence and severity of treatment-emergent adverse events (TEAEs) and recommended phase 2 dose (R2PD). Secondary endpoints included incidence and severity of adverse events (AEs), efficacy and pharmacokinetics. Response was assessed per Lugano 2014 criteria by investigators.
Results:
As of April 2, 2026, LBCL 12 patients had received prizlon-cel infusion, of whom 2 had HGBL-DH/TH. The median age was 62.0 years (range, 25-76), with ~40% patients aged ≥ 65 years. A total of 58.3% patients had refractory lymphoma and 50% patients never achieved CR to prior therapies. All patients were heavily pretreated, with a median of 2 prior lines of therapy (range, 2-4). Six patients received bridging therapy.
No DLTs were observed. Among the 12 patients, 75.0% experienced CRS, all of which were grade 1–2. The median time to CRS onset was 2 days (range: 1–4), and the median duration was 8 days (range: 5–10). No ICANS was observed. Grade 3 or higher cytopenias not resolved by day 30 after prizlon-cel infusion occurred in 6 patients (50.0%), including 4 (33.3%) with neutropenia and 2 (16.7%) with thrombocytopenia. Grade 3 or higher infections were observed in 4 (33.3%) patients.
As of the data cutoff date, all patients had completed 2-year follow-up. ORR was 83.3%, and all of which were CR. The ORR and CR rate at 3 months were 75.0% and 66.7%, respectively. Median time to response was 1.0 month (range, 0.9-2.8), with the median time to CR being 1.0 month (range, 0.9-9.1). With a median follow-up of 29.9 months (range, 2.9-36.2), median DOR, PFS and OS were all not reached. The estimated 2-year DOR, PFS and OS rates were 80.0%, 66.7% and 75.0%, respectively.
The pharmacokinetic profile showed prizlon-cel had a robust expansion and long-term persistence, with a median Cmax of 69,499.4 copies/g gDNA, a median Tmax of 15.0 days and a median Tlast of 373.5 days.
Conclusion:
The preliminary safety, efficacy, and PK data support 2.5×106 CAR-T cells/kg as the RP2D. At this dose, prizlon-cel demonstrated a favorable safety profile and deep, durable responses in patients with r/r LBCL. The ongoing ELEVATION Phase 2 study will further confirm the durability and depth of response to prizlon-cel.
DISCLOSURES
Yuqin Song, MD: F. Hoffmann-La Roche Ltd, BeOne Medicines, AstraZeneca - Honoraria; F. Hoffmann-La Roche Ltd, AbbVie, AstraZeneca, BeOne - Honoraria; Peking University Cancer Hospital - Current Employment